Initially he planned to retire at the end of the year; however health issues have accelerated his retirement plans.
Parent company SSM Health has appointed David Fields, president of Dean Health Plan, to serve as interim president and CEO of Navitus while a national search is conducted for Seligman's successor.
Seligman served as president and CEO for the past 12 years of the company's 16-year history.
Under his leadership, Navitus has flourished growing from a PBM with 80 employees, 20 clients and 500,000 members to an industry leader with 850 employees, serving over 600 clients and 6m members.
He also brought innovation to a new space, expanding the pass-through business model into specialty pharmacy with the launch of Lumicera Health Services.
Prior to joining Navitus, Seligman held a variety of senior leadership roles in managed care, provider systems, health insurance, retail, mail service, pharmacy benefit management and consulting with nationally-recognized organisations.
Navitus Health Solutions, a division of SSM Health, serves as a full pass through pharmacy benefit manager and industry alternative to traditional models.
As such, Navitus is committed to taking the unnecessary costs out of pharmacy benefits to make prescriptions more affordable for plan sponsors (i.e. employers, health plans, unions, governments, etc.) and their members.
By combining a unique pass through approach that returns 100% of rebates with a focus on lowest-net-cost medications and comprehensive clinical care programmes, Navitus helps reduce costs and improve member health.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer